1. Woldeamanuel YW, Cowan RP. Migraine affects 1 in 10 people worldwide featuring recent rise: A systematic review and meta-analysis of community-based studies involving 6 million participants, J Neurol Sci 2017;372:307–15.
2. Vetvik KG, MacGregor EA. Sex differences in the epidemiology, clinical features, and pathophysiology of migraine. Lancet Neurol 2017;16:76–87.
3. Lipton RB, Bigal ME. Migraine: epidemiology, impact, and risk factors for progression. Headache 2005;45 Suppl 1:S3–S13.
4. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016;388:1545–602.
5. Lipton RB, Silberstein SD. Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention Headache 2015;55 Suppl 2:103–22.
6. Diamond S, Bigal ME, Silberstein S, et al. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study. Headache 2007;47:355–63.
7. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study. Lancet 2012;380:2163–96.
8. Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001;41:646–57.
9. Stewart WF, Ricci JA, Chee E, et al. Lost productive time and cost due to common pain in the US workforce. JAMA 2003;290:2443–54.
10. Hawkins K, Wang S, Rupnow M. Direct cost burden among insured US employees with migraine. Headache 2008;48:553–63.
11. Lipton RB, Serrano D, Holland S, et al. Barriers to the diagnosis and treatment of migraine: Effects of sex, income, and headache features. Headache 2013;53:81–92.
12. Dodick DW, Loder EW, Manack Adams A, et al. Assessing barriers to chronic migraine consultation, diagnosis, and treatment: Results from the chronic migraine epidemiology and outcomes (CaMEO) study. Headache 2016;56:821–34.
13. Young WB, Park JE, Tian IX, Kempner J. The stigma of migraine. PLoS One 2013;8(1):e54074.
14. Mia M, Ashna S, Audrey H. A migraine management training program for primary care providers: an overview of a survey and pilot study findings, lessons learned, and considerations for further research. Headache 2016;56:725–40.
15. Lipton RB, Amatniek JC, Ferrari MD, Gross M. Migraine: identifying and removing barriers to care. Neurology 1994;44(6 Suppl 4):S63–8.
16. Knapp RD Jr. Reports from the past 2. Headache 1963;3:112–22.
17. Levine M, Wolff HG. Cerebral circulation: afferent impulses from the blood vessels of the pia. Arch Neurol Psychiat 1932;28:140.
18. Amin FM, Asghar MS, Hougaard A, et al. Magnetic resonance angiography of intracranial and extracranial arteries in patients with spontaneous migraine without aura: a cross sectional study. Lancet Neurol 2013;12:454–61.
19. Goadsby PJ, Holland PR, Martins-Oliveira M, et al. Pathophysiology of migraine—a disorder of sensory processing. Physiol Rev 2017;97:553–622.
20. Goadsby PJ. Pathophysiology of migraine. Ann Indian Acad Neurol 2012;15(Suppl 1):S15–S22.
21. Puledda F, Messina R, Goadsby PJ, et al. An update on migraine: current understanding and future J Neurol 2017 Mar 20.
22. Vinogradova LV. Comparative potency of sensory-induced brainstem activation to trigger spreading depression and seizures in the cortex of awake rats: implications for the pathophysiology of migraine aura. Cephalalgia 2015;35:979–86.
23. Bahra A, Matharu MS, Buchel C, et al. Brainstem activation specific to migraine headache. Lancet 2001;357:1016–7.
24. Schulte LH, May A. The migraine generator revisited: continuous scanning of the migraine cycle over 30 days and three spontaneous attacks. Brain 2016;139:1987–93.
25. Noseda R, Jakubowski M, Kainz V, et al. Cortical projections of functionally identified thalamic trigeminovascular neurons: implications for migraine headache and its associated symptoms. J Neurosci 2011;31:14204–17.
26. Noseda R, Kainz V, Jakubowski M, et al. A neural mechanism for exacerbation of headache by light. Nat Neurosci 2010;13:239–45.
27. Puledda F, Messina R, Goadsby PJ. An update on migraine: current understanding and future directions. J Neurol 2017 Mar 20.
28. Coppola G, Di Lorenzo C, Schoenen J, Pierelli F. Habituation and sensitization in primary headaches. J Headache Pain 2013;14:65.
29. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 2013;33:629–808.
30. Yusheng H, Y Li. Typical aura without headache: a case report and review of the literature J Med Case Rep 2015;9:40.
31. Buture A, Khalil M, Ahmed F. Iatrogenic visual aura: a case report and a brief review of the literature Ther Clin Risk Manag 2017;13:643–6.
32. Lipton RB. Tracing transformation: Chronic migraine classification, progression, and epidemiology. Neurology 2009;72:S3–7.
33. Lipton RB. Headache 2011;51;S2:77–83.
34. Scher AI, Stewart WF, et al. Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain 2003;106:81–9.
35. Bigal ME, Lipton RB, Holland PR, Goadsby PJ. Obesity, migraine, and chronic migraine: possible mechanisms of interaction. Neurology 2007;68:1851–61.
36. Wolff HG. Stress and disease. Springfield, IL: Charles C. Thomas; 1953.
37. Guidetti V, Galli F, Fabrizi P, et al. Headache and psychiatric comorbidity: clinical aspects and outcome in an 8-year follow-up study. Cephalalgia 1998;18:455–62.
38. Mongini F, Keller R, Deregibus A, et al. Personality traits, depression and migraine in women: a longitudinal study. Cephalalgia 2003;23:186–92.
39. Hung CI, Liu CY, Yang CH, Wang SJ. The impacts of migraine among outpatients with major depressive disorder at a two-year follow-up. PLoS One 2015;10:e0128087.
40. Frishberg BM, Rosenberg JH, Matchar DB, et al. Evidence-based guidelines in the primary care setting: neuroimaging in patients with nonacute headache. St Paul: US Headache Consortium; 2000.
41. Headache Measurement Set 2014 Revised. American Academy of Neurology. Accessed at www.aan.com/uploadedFiles/Website_Library_Assets/Documents/3.Practice_Management/2.Quality_Improvement/1.Quality_Measures/1.All_Measures/2014.
42. Taylor FR. Lifestyle changes, dietary restrictions, and nutraceuticals in migraine prevention. Techn Reg Anesth Pain Manage 2009;13:28–37.
43. Varkey E, Cider A, Carlsson J, Linde M. Exercise as migraine prophylaxis: A randomized study using relaxation and topiramate as controls. Cephalalgia 2011;14:1428–38.
44. Ahn AH. Why does increased exercise decrease migraine? Curr Pain Headache Rep 2013;17:379.
45. Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: The American Headache Society evidence assessment of migraine pharmacotherapies. Headache 2015;55:3–20.
46. Belvis R, Mas N, Aceituno A. Migraine attack treatment : a tailor-made suit, not one size fits all. Recent Pat CNS Drug Discov 2014;9:26–40.
47. Bigal ME, Serrano D, Buse D, et al. Acute migraine medications and evolution from episodic to chronic migraine: A longitudinal population-based study. Headache 2008;48:1157–68.
48. Bigal ME, Rapoport AM, Sheftell FD, et al. Transformed migraine and medication overuse in a tertiary headache centre--clinical characteristics and treatment outcomes Cephalalgia 2004;24:483–90.
49. Silberstein SD, Holland S, Freitag F, et al; Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012;78:1337–45.
50. Diener HC, Dodick DW, Aurora SK, et al. OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial Cephalagia year;30:804–14.
51. Wells RE, Markowitz SY, Baron EP, et al. Identifying the factors underlying discontinuation of triptans. Headache 2014;54:278–89.
52. Holland S, Fanning KM, Serrano D, et al. Rates and reasons for discontinuation of triptans and opioids in episodic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study. J Neurol Sci 2013;326:10–7.
53. Seng EK, Rains JA, Nicholson RA, Lipton RB. Improving medication adherence in migraine treatment. Curr Pain Headache Rep 2015;19:24.
54. Nicholson RA, Buse DC, Andrasik F, Lipton RB. Nonpharmacologic treatments for migraine and tension-type headache: how to choose and when to use. Curr Treatment Opt Neurol 2011;13:28–40.
55. Probyn K, Bowers H, Mistry D, et al. Non-pharmacological self-management for people living with migraine or tension-type headache: a systematic review including analysis of intervention components BMJ Open 2017;7:e016670.
56. Lemstra M, Stewart B, Olszynski WP. Effectiveness of multidisciplinary intervention in the treatment of migraine: a randomized clinical trial. Headache 2002;42:845–54.
57. John PJ, Sharma N, Sharma CM, Kankane A. Effectiveness of yoga therapy in the treatment of migraine without aura: a randomized controlled trial. Headache 2007;47:654–61.
58. Harris P, Loveman E, Clegg A, et al. Systematic review of cognitive behavioural therapy for the management of headaches and migraines in adults Br J Pain 2015;9:213–24.
59. Kropp P, Meyer B, Meyer W, Dresler T. An update on behavioral treatments in migraine - current knowledge and future options. Expert Rev Neurother 2017:1–10.
60. Sullivan A, Cousins S, Ridsdale L. Psychological interventions for migraine: a systematic review. J Neurol 2016;263:2369–77.
61. Holroyd KA, Cottrell CK, O’Donnell FJ, et al. Effect of preventive (beta blocker) treatment, behavioural migraine management, or their combination on outcomes of optimised acute treatment in frequent migraine: randomised controlled trial. BMJ 2010;341:c4871.
62. Penzien DB, Rains JC, Andrasik F. Behavioral management of recurrent headache: three decades of experience and empiricism. Appl Psychophysiol Biofeedback 2002;27:163–81.
63. Smith TR, Nicholson RA, Banks JW. A primary care migraine education program has benefit on headache impact and quality of life: results from the mercy migraine management program. Headache 2010;50:600–12.
64. Rothrock JF, Parada VA, Sims C, et al.The impact of intensive patient education on clinical outcome in a clinic-based migraine population. Headache 2006;46:726–31.